Latest Updates
-
A Hotel on Wheels: Bihar Rolls Out Its First Luxury Caravan Buses -
Bharti Singh-Haarsh Limbachiyaa Welcome Second Child, Gender: Couple Welcome Their Second Baby, Duo Overjoyed - Report | Bharti Singh Gives Birth To Second Baby Boy | Gender Of Bharti Singh Haarsh Limbachiyaa Second Baby -
Bharti Singh Welcomes Second Son: Joyous News for the Comedian and Her Family -
Gold & Silver Rates Today in India: 22K, 24K, 18K & MCX Prices Fall After Continuous Rally; Check Latest Gold Rates in Chennai, Mumbai, Bangalore, Hyderabad, Ahmedabad & Other Cities on 19 December -
Nick Jonas Dancing to Dhurandhar’s “Shararat” Song Goes Viral -
From Consciousness To Cosmos: Understanding Reality Through The Vedic Lens -
The Sunscreen Confusion: Expert Explains How to Choose What Actually Works in Indian Weather -
On Goa Liberation Day 2025, A Look At How Freedom Shaped Goa Into A Celebrity-Favourite Retreat -
Daily Horoscope, Dec 19, 2025: Libra to Pisces; Astrological Prediction for all Zodiac Signs -
Paush Amavasya 2025: Do These Most Powerful Rituals For Closure On The Final Amavasya Of The Year
DCGI Approves India's First qHPV Vaccine Against Cervical Cancer
Update: As per recent news reports, the DCGI subject expert committee has approved Serum Institute's indigenously created qHPV vaccination for cervical cancer. It will be India's first indigenous cervical cancer vaccine.

Serum Institute of India (SII) has applied to the country's drug regulator seeking market authorisation to manufacture indigenously developed India's first Quadrivalent Human Papillomavirus vaccine (qHPV) against cervical cancer, official sources said on Wednesday, June 8.
The Pune-based firm has applied for market authorisation after completing the phase 2/3 clinical trial with support of the Department of Biotechnology to ensure its early availability in the country, they said.
In the application to the Drugs Controller General of India (DCGI), Prakash Kumar Singh, director (government and regulatory affairs) at SII, said the vaccine CERVAVAC has demonstrated a robust antibody response that is nearly 1,000 times higher than the baseline against all targeted HPV types and in all dose and age groups.
The SII is also learnt to have made a presentation before the working group of HPV under the chairmanship of Dr NK Arora constituted separately by the NTAGI to review the data and usefulness of this vaccine on Wednesday, the sources said.

In the application, Singh mentioned that every year lakhs of women are diagnosed with cervical cancer as well as few other cancers and death ratio is also very high.
Cervical cancer in India ranks as the second-most frequent cancer among women between 15 and 44 years of age.
"Also, it is noteworthy that presently, our country is fully dependent on foreign manufacturers for the HPV vaccine. In line with the philosophy of our group & under the leadership of our CEO, Dr Adar C Poonawalla, it has always been our endeavour to make available high quality 'Made in India' vaccines at an affordable price for people of our country and the world at large," Singh said in the application.
"Like many other indigenous life-saving vaccines, we are committed to making our country 'ATMANIRBHAR' for India's first indigenous life-saving qHPV vaccine also. This will fulfill the dream of our Hon'ble Prime Minister Narendra Modi 'VOCAL FOR LOCAL' and 'MAKING IN INDIA FOR THE WORLD' and will ensure the prevention of cancers caused by Human Papillomavirus (Type 6, 11, 16 & 18) vaccine recombinant," Singh is learnt to have said in the application.
Disclaimer: The information provided in this article is for general informational and educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or a qualified healthcare provider with any questions you may have regarding a medical condition.



Click it and Unblock the Notifications











